Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2012-07-27 / Int J Hyperthermia 2012;28(7):597-604Cell-type-specific innate immune response to oncolytic Newcastle disease virus
/in International Publications, Newcastle Disease Virus /von 2012-07-18 / Viral Immunol. 2012 Aug;25(4):268-76Successful treatment of solitary bone metastasis of non-small cell lung cancer with bevacizumab and hyperthermia
/in Hyperthermia, International Publications, NSCLC /von 2012-07-03 / Pathol. Oncol. Res. 2013 Jan;19(1):119-22Bugs and drugs: oncolytic virotherapy in combination with chemotherapy
/in International Publications, Newcastle Disease Virus /von 2012-07-01 / Curr Pharm Biotechnol 2012 Jul;13(9):1817-33Recent clinical experience with oncolytic viruses
/in International Publications, Newcastle Disease Virus /von 2012-07-01 / Curr Pharm Biotechnol 2012 Jul;13(9):1834-41Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation
/in Dendritic Cells, International Publications /von 2012-07-01 / Immunotherapy 2012 Jul;4(7):703-18
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution